Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - January 20, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio an
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-20 9:30 AM EST | Phio Pharmaceuticals Corp.
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, in
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-20 8:00 AM EST | BioVaxys Technology Corp.
Therma Bright Sells an Additional 200-Units of Venowave(TM) to Strategic Distribution Partner Gen-X Med
Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce it has received a follow-on order for an additional 200 Venowave™ VW5 units from its Texas-based distribution partner, Gen-X Med. This latest transaction marks the expansion of the relationship between the
Technology, Biotechnology, Health
2026-01-20 6:30 AM EST | Therma Bright Inc.
Entheon Announces Execution of Business Combination Agreement with Nutravisor
Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into a definitive business combination agreement (the "Business Combination Agreement") with Nutravisor Inc. ("Nutravisor"), dated January 19, 2026, pursuant to which the parties have agreed to complete a business combination involving a "three-cornered" amalgamation of
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2026-01-19 5:28 PM EST | Entheon Biomedical Corp.
Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000
Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") is pleased to announce a non-brokered private placement offering of secured convertible debentures ("Debentures") for gross proceeds of up to $1,200,000 (the "Offe
2026-01-19 8:00 AM EST | Telo Genomics Corp.
Hemostemix Receives FDA Support for Its Basket Protocol Approach
Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, announces the successful completion of its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administra
Biotechnology, Pharmaceuticals, Health
2026-01-16 12:26 PM EST | Hemostemix Inc.
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with a sole underwriter and sole bookrunner pursuant to which the underwriter (the "Underwriter") has agreed to purchase for resale 10,384,616
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-01-16 8:46 AM EST | Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with Canaccord Genuity Corp. (the "Underwriter") as the sole underwriter and sole bookrunner pursuant to which the Underwriter has agreed to p
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-01-16 8:42 AM EST | Cardiol Therapeutics Inc.
Optimi Health Announces Equity Incentive Grants and Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced a series of equity compensation and marketing initiatives designed to support its growth strategy and enhance market awareness. Equity Incentive Grants Optimi announces that, pursuant to its equity incentive plan and subject
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-16 7:00 AM EST | Optimi Health Corp.
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical t
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-15 8:45 AM EST | Phio Pharmaceuticals Corp.
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Mo
Technology, Biotechnology, Healthcare and Hospitals
2026-01-15 8:30 AM EST | BioMark Diagnostics, Inc.
OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (<1year) Pre-specified pathway analysis strategy developed as a result of immune biomarker pathway data generated from 118-patient canine metastatic osteosarcoma study published in February 2025 demonstrates translational power of Comparati
2026-01-15 7:00 AM EST | OS Therapies
Scryb Inc. Provides Early Warning Update on Holdings in Cybeats Technologies Corp.
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) ("Scryb'' or the "Company"), is issuing this release to report information concerning its holdings in Cybeats Technologies Corp. (the "Issuer" or "Cybeats"). Scryb's total share ownership position of Cybeats is unchanged following all transactions outlined in this press release. Scryb outlines below that it accepted common shares in lieu of cash repayment from Cybeats Techno
Biotechnology, Healthcare and Hospitals, Health
2026-01-14 9:08 PM EST | Scryb Inc.
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of ketamine, psychedelics, and GLP-1 drugs for neuropsychiatric and obesity disorders, today announced a new strategic initiative to expand its PharmaPatch™ microneedle patch platform into GLP-1 therapies for the potential treatment of obesity. PharmaT
Biotechnology, Pharmaceuticals
2026-01-14 8:00 AM EST | PharmaTher Holdings Ltd.
Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading producer of prescribed psychedelic treatments for mental health therapies, today announced that management has been invited to present at the Sidoti Micro-Cap Virtual Conference on January 21-22, 2026. Chief Executive Officer Dane Stevens is scheduled to host virtual one-on-one meetings with institutional invest
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-14 7:30 AM EST | Optimi Health Corp.
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or Nasdaq Capital Markets national stock exchange in the first half of 2026 (1H/2026) OSTX shareholders expected to receive one (1) share of OSAH for every ten (10) shares of OSTX owned as of the expected to-be-determined 1H/2026 record date OSAH to focus primarily on the re-establishment of USDA conditional approval and commercialization of
2026-01-14 7:00 AM EST | OS Therapies
TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage
Highlights ROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibility Confirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investment Supports TempraMed's planned payor pilot programs aimed at confirming savings and securing reimbursement coverage Establishe
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-14 2:00 AM EST | TempraMed Technologies Ltd.
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Toronto, Ontario--(Newsfile Corp. - January 13, 2026) - Cardiol Therapeutics Inc. (NASDAQ:
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-01-13 7:27 AM EST | Cardiol Therapeutics Inc.
TempraMed Closes C$2.5 Million Fully Subscribed Private Placement
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce the fully subscribed closing of its previously announced non-brokered private placement (the "Offering"), issuing 3,322,153 units (each, a "Unit") at a price of $0.76 p
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-12 5:30 PM EST | TempraMed Technologies Ltd.
OS Therapies Enters into Warrant Inducement Agreements
New York, New York--(Newsfile Corp. - January 12, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("O
2026-01-12 8:01 AM EST | OS Therapies